BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...kallikrein (KLKB1) inhibitor into Phase II testing. Venrock was an early investor in HAE company Dyax Corp....
...acquired by Shire plc and is now part of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Dyax's...
BioCentury | Aug 31, 2018
Clinical News

FDA approves Shire's Takhzyro, first mAb to prevent HAE

...Shire obtained Takhzyro via its 2016 acquisition of Dyax Corp. Under the terms of the acquisition, Dyax...
...CVR) worth $646 million tied to the drug's U.S. approval (see "Shire HAE Treatment from Dyax...
...hours. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Takhzyro lanadelumab-flyo Business: Inflammation Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire...
BioCentury | Aug 23, 2018
Company News

FDA approves Shire’s Takhzyro, first mAb to prevent HAE

...Shire obtained Takhzyro via its 2016 acquisition of Dyax Corp. Under the terms of the acquisition, Dyax...
...CVR) worth $646 million tied to the drug's U.S. approval (see "Shire HAE Treatment from Dyax...
...to $170.42 on NASDAQ. News of the approval came after market hours. Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire...
BioCentury | Mar 2, 2018
Clinical News

Priority review for Shire's HAE prophylactic

...HELP trial, meeting the study's primary endpoint. Shire obtained lanadelumab via its 2016 acquisition of Dyax Corp....
BioCentury | Feb 23, 2018
Company News

Priority Review for Shire's HAE prophylactic

...HELP trial, meeting the study's primary endpoint. Shire obtained lanadelumab via its 2016 acquisition of Dyax Corp....
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc. in 2014 and Dyax Corp....
...Jan. 18, 2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc. in 2014 and Dyax Corp....
...44p to 3,708.50p in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini...
BioCentury | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

...gained lanadelumab, a human mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp....
BioCentury | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

...gained lanadelumab, a human mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp....
BioCentury | May 19, 2017
Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

...1H18 for an MAA submission. The company gained lanadelumab in 2016 through its acquisition of Dyax Corp....
Items per page:
1 - 10 of 567
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...kallikrein (KLKB1) inhibitor into Phase II testing. Venrock was an early investor in HAE company Dyax Corp....
...acquired by Shire plc and is now part of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Dyax's...
BioCentury | Aug 31, 2018
Clinical News

FDA approves Shire's Takhzyro, first mAb to prevent HAE

...Shire obtained Takhzyro via its 2016 acquisition of Dyax Corp. Under the terms of the acquisition, Dyax...
...CVR) worth $646 million tied to the drug's U.S. approval (see "Shire HAE Treatment from Dyax...
...hours. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Takhzyro lanadelumab-flyo Business: Inflammation Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire...
BioCentury | Aug 23, 2018
Company News

FDA approves Shire’s Takhzyro, first mAb to prevent HAE

...Shire obtained Takhzyro via its 2016 acquisition of Dyax Corp. Under the terms of the acquisition, Dyax...
...CVR) worth $646 million tied to the drug's U.S. approval (see "Shire HAE Treatment from Dyax...
...to $170.42 on NASDAQ. News of the approval came after market hours. Elizabeth S. Eaton Lanadelumab (SHP643, dx-2930) Dyax Corp. Shire...
BioCentury | Mar 2, 2018
Clinical News

Priority review for Shire's HAE prophylactic

...HELP trial, meeting the study's primary endpoint. Shire obtained lanadelumab via its 2016 acquisition of Dyax Corp....
BioCentury | Feb 23, 2018
Company News

Priority Review for Shire's HAE prophylactic

...HELP trial, meeting the study's primary endpoint. Shire obtained lanadelumab via its 2016 acquisition of Dyax Corp....
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc. in 2014 and Dyax Corp....
...Jan. 18, 2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc. in 2014 and Dyax Corp....
...44p to 3,708.50p in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini...
BioCentury | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

...gained lanadelumab, a human mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp....
BioCentury | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

...gained lanadelumab, a human mAb against plasma kallikrein (KLKB1), in 2016 through its acquisition of Dyax Corp....
BioCentury | May 19, 2017
Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

...1H18 for an MAA submission. The company gained lanadelumab in 2016 through its acquisition of Dyax Corp....
Items per page:
1 - 10 of 567